BridgeBio Pharma Has Promising News

BridgeBio Pharma Granted Fast Track Designation for Encaleret
BridgeBio Pharma (BBIO) announced the U.S. FDA granted Fast Track designation for Encaleret – a treatment of autosomal dominant hypocalcemia (ADH1), on World Hypoparathyroidism Awareness Day, an annual global awareness event meant to support people who are living with ADH1 and with other types of hypoparathyroidism.

ADH1 is a rare, genetic form of . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.